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1. Introduction 
Atherosclerosis is increasingly considered as a low grade inflammatory response of the 
arterial wall to a variety of stimuli [Fuster&Lewis, 1994; Libby, 2001]. It is accepted that 
the adhesion of circulating leukocytes and monocytes to endothelial cells (EC) and 
subsequent transendothelial migration are an important step in the initiation and the 
development of atherosclerotic lesions [Hillis&Flapan, 1998; Jang, 1994]. This process is 
mediated by receptors expressed on the surface of vascular EC – cell adhesion molecules 
(CAM) under the action of an enhanced oxidative stress, lipopolysaccharide and 
proinflammatory cytokines. Vascular cell adhesion molecule (VCAM-1) and intercellular 
adhesion molecule (ICAM-1) are two members of the immunoglobulin gene superfamily 
that play important but different roles in the adhesion of blood cells to the vascular 
endothelium.  The significance of these molecules in the course of atherogenesis is 
confirmed by their immunohistochemically established elevated expression in the 
atherosclerotic plaques [Cybulsky&Gimbronejr, 1991; O’Brien et al., 1993] and by 
experimental models proving a delayed lesion development in case of their absence 
[Cybulsky et al., 2001].  
Circulating forms of adhesion molecules that have been described are probably generated 
by cleavage to a site close to membrane insertion. The amount of ICAM-1 released has been 
demonstrated to be directly correlated with the surface expression of ICAM-1 in EC in 
culture and a correlation between plasma VCAM-1 and VCAM-1 mRNA has been reported 
in human atherosclerotic aorta [Leuwenberg et al., 1992; Pigott et al., 1992]. 
Levels of soluble cell adhesion molecules have been postulated to be useful risk predictor of 
cardiovascular events in healthy populations and various settings of ischemic heart disease 
[de Lemos et al., 2000; Hwang et al., 1997; Mulvihill et al., 2000, 2001; O’Malley et al., 2001; 
Ridker et al., 1998]. Nonetheless, the pathologic role of different soluble adhesion molecules 
in various stages of coronary artery disease is not fully defined.  
Two electrocardiographic markers - ventricular arrhythmias (VA), [Bigger et al., 1981; 
Farrell et al., 1991; Kostis et al., 1987] and impaired cardiac autonomic function, as indicated 
by depressed heart rate variability (HRV), [Bigger at al., 1992; Farrell et all, 1991; 
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Hartikainen et al., 1996; Kleiger  et al., 1987; Lanza et al., 1998, 2006; La Rovere et al., 1998] 
have been shown to predict mortality among patients recovering from acute myocardial 
infarction (MI). However there are only limited data about the prognostic value of 
depressed HRV in the whole spectrum of patients with ACS and few attempts to quantify 
the exact value of soluble adhesion molecules and HRV in the cumulative risk assessment of 
patients with ACS [Kennon et al., 2008; Lanza et al., 2006]. 
Previous studies have shown that statin treatment improve the prognosis in patients with 
acute coronary syndromes [Kinlay et al., 2003; Ridker at al., 2005]. The reduction of clinical 
events secondary to lipid lowering has traditionally been attributed to reduction of 
cholesterol deposition and facilitation of cholesterol efflux from coronary plaques. However, 
several studies have recently suggested that the beneficial effects of statins in atherosclerotic 
disease may not be limited to the lipid-lowering effects of these drugs. Possible explanations 
for the observed reduction of morbidity and mortality with statin use include improvement 
of endothelial function, plaque stabilisation, and inhibition of the inflammatory response 
associated with atherosclerosis [Liao 2003; Ray&Cannon, 2005]. In the last years an 
antiarrhythmic effect of statins has been suggested and reported as a possible contributing 
mechanism. 
The aim of this study was:  
1. To assess heart rate variability and soluble adhesion molecules ICAM-1 (intercellular 
adhesion molecule-1) and VCAM-1 (vascular cells adhesion molecule-1) in patients 
with coronary artery disease and healthy control and to evaluate the usefulness of the 
markers of impaired autonomic function and endothelial activation as predictors of 
adverse prognosis in patients with acute coronary syndromes.  
2. The impact of early initiation of low and moderate-dose rosuvastatin treatment on 
autonomic function and concentrations of soluble adhesion molecules during the first 
12 weeks post ACS without ST segment elevation. 
2. Methods 
2.1 Study protocol 
The study consisted of two phases. In the first phase two groups of patients with coronary 
artery disease (acute coronary syndromes without ST segment elevation and stable angina 
pectoris) and one control group of subjects were included for comparisons of soluble 
levels of adhesion molecules and heart rate variability. Between December 2001 and July 
2002, a total number of 136 patients were involved in the study. Patients were divided 
into three groups according to the clinical diagnosis. The first group consisted of 75 
patients with non-ST segment elevation ACS (unstable angina and non ST elevation 
myocardial infarction). Unstable angina (UA) patients (n=57) had ischemic chest pain at 
rest within the preceding 48 hours that had developed in the absence of an extracardiac 
precipitating cause with either ST segment depression of >0.1 mV or T wave inversion in 
two or more contiguous leads on the presenting 12 lead ECG. Patients with non ST 
elevation myocardial infarction (n=18) had similar diagnostic criteria along with elevation 
of serum creatine kinase, without the evolution of pathological q waves. The second 
group consisted of 36 patients with stable angina pectoris (SAP) who had typical 
exertional angina pectoris and positive stress test. Patients with angina at rest were 
excluded from this group. The control group comprised of 25 healthy volunteers in the 
same age of distribution, without angina symptoms and with normal physical 
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examination and stress test. Subjects with acute or chronic inflammatory diseases, 
malignancies, renal insufficiency, and severe liver disease, on immunosuppressive and 
antibiotic treatment were excluded from the study. Also excluded were patients with 
acute ST elevation myocardial infarction, diabetes mellitus, and history of myocardial 
infarction, surgical intervention or major trauma within the preceding month.   
A six months follow-up of patients with ACS was assessed by regular clinical examination 
for every month. Primary outcome was defined as cardiac death, non-fatal myocardial 
infarction or recurrent hospital admission for severe unstable angina. After the 6-month 
period of observation the study population was divided into two groups – with favorable 
course of the disease and with occurrence of adverse coronary events. 
In the second phase other 30 patients with ACS were allocated into two groups, and 
received rosuvastatin 10 mg/day (n =16, mean age 57.25±2.2 years) or rosuvastatin 20 
mg/day (n =14, mean age  57.64±3.1 years). The randomization was carried out by the 
adaptive dynamic random allocation method irrespective of serum lipids levels. A follow-
up assessment of both HRV on ambulatory ECG monitoring and adhesion molecules levels 
was performed during study period of 12 weeks. All patients were under treatment with the 
same medications during the acute phase of the episode (aspirin, nitrates, beta blockers, 
ACE inhibitors), according to the guidelines. 
2.2 Biochemical analysis 
Blood samples from ACS patients were collected after admission in the ICU prior to the 
onset of the antiischemic and anticoagulant therapy with a closed Vacutainer system 
(Beckton Dickinson, NJ, USA) and after 12 weeks for patients included into the second 
phase of the study. In SAP group and in controls, blood samples were collected at the time 
of clinical admission. The serum was separated after centrifugation at 3000 g for 10 min until 
1 hour after taking the samples and sent in Department of Clinical Laboratory, Saint Anne 
University hospital for analyses of creatine kinase, cholesterol and triglycerides levels as a 
part of routine patient management. Two aliquots of the serum were centrally stored at -
80°C and sent in batches to the Department of Clinical Laboratory and Clinical 
Immunology, Medical university, Sofia (for analyses of cTnT and hsCRP) and to the Section 
of Molecular Immunology, Bulgarian Academy of Sciences, Sofia (for analyses of VCAM-1 
and ICAM-1). Determination of cTnT, hsCRP and soluble adhesion molecules levels was 
performed at the end of the study period, blinded to patients’ histories and allocated 
treatment.  
Quantitative detection of serum concentrations of sVCAM-1 and sICAM-1 was performed 
using an enzyme linked immunosorbent assay (ELISA) technique employing a 
commercially available assay kit (BenderMed Sysytems, Vienna, Austria). The intra- and 
interassay coefficients of variation were 3.1%, 5.2% for VCAM-1 and 4.1%, 7.6% for ICAM-1 
respectively. The levels of cardiac troponin T (cTnT) were determined by a third generation 
troponin STAT electrochemiluminescent immunoassay on the ELECSYS 1010 (Roche 
Diagnostics, Basel, Switzerland) with the detection limit at 0.01 ng/ml and a total coefficient 
of variation (CV) of 6% at 5.07 ng/ml and 9.3% CV at 0.10 ng/ml. High-sensitivity C-
reactive protein was measured with a CardioPhase hsCRP immunonephelometric assay 
(Dade Behring Inc) on BN systems. The detection limit was 0.175 mg/l with a total CV of 
7.6% at 0.41 mg/l.  
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2.3 Holter monitoring 
Patients underwent 24 h ECG Holter monitoring within 24 h of admission with two-channel 
tape recorders and monitoring two bipolar chest leads.  Cardiac autonomic function was 
assessed by frequency-domain HRV analyses for the entire 24 hours. Frequency domain 
HRV was assessed in the frequency range of 0 to 0.5 Hz by fast-Fourier transform spectral 
analysis, with a spectral resolution of 0.0005 Hz. The amplitude of the following frequency-
domain HRV variables was obtained: very low frequency (0.0033 to 0.04 Hz), low frequency 
(0.04 to 0.15 Hz), and high frequency (0.15 to 0.40 Hz). Further, the ratio of low to high 
frequency was calculated. 
2.4 Statistical analysis 
Any quantitative parameters under investigation were presented as a mean value and 
standart deviation. Any qualitative parameters under investigation were presented as a 
number and percentage. Student’s t test or paired sample t-test was used to compare the 
quantitative parameters in the groups with a normal distribution. Mann-Whitney’s or 
Wilcoxon signed rank non-parametric analysis is applied to compare the quantitative 
parameters of non-Gaussian distribution such as cTnT, hsCRP, sICAM-1, sVCAM-1 and 
parameters of HRV. Comparison of the categorical variables was performed by Pearson’s 
x2test and Fisher’s test. Receiver-operating characteristics (ROC) analysis was performed to 
estimate the potential of the variable tested to discriminate between patients with and 
without cardiovascular events during follow-up. To identify variables as independent 
predictors of CV events we calculated various multivariate Cox regression models with 
stepwise adjustment for univariate predictors possibly confounding the examined variable. 
Probability values of p<0,05 were considered statistically significant. All analyses were 
performed with SPSS, 9.0 version for Windows. 
3. Results 
3.1 Markers of endothelial activation and impaired autonomic function in patients with 
acute coronary syndromes – Potential prognostic implication 
3.1.1 Characteristics of the study population 
Table 1 demonstrates clinical characteristics and biochemical data of all study groups. There 
were no significant differences among study groups regarding age, gender, family history 
and smoking status. The patients with coronary artery disease (acute coronary syndromes 
and stable angina) had significantly higher rates of hypertension and dyslipidaemia 
compared with healthy control group. The presence of coronary risk factors was equal 
among groups with acute coronary syndromes and stable angina pectoris. Eight of the 
patients in the control group (32%) were on antihypertensive medications. The 
corresponding number of patients on antihypertensive medications in ACS group was 48 
(64%) and 21 (61%) in stable angina pectoris group. All soluble ICAM-1, VCAM-1 and 
hsCRP significantly discriminated between patients with ACS and SAP (p=0.014, 0.05 and 
0.025 respectively) and control subjects (p<0.001, 0.05 and 0.048).  Soluble ICAM-1 and 
hsCRP were also elevated in patients with SAP compared with control group whereas no 
difference in sVCAM-1 was found (p<0.001, 0.05 and 0.4). In opposite, all the parameters of 
the frequency domain HRV tented to be lower in patients with ACS compared with stable 
angina and control group. In healthy subjects VLF, LF and HF were elevated, but LF/HF 
ratio was lower in comparison with stable angina patients (p=0.006).   
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Variable 
ACS 
Group 1 
Stable AP 
Group 2 
Ǿ1 Control 
Group 3 
Ǿ2 Ǿ3 
Number 75 36  25   
Age 57.8±8.8 57.8±8.7 1 55.6±9.2 0.3 0.4 
Male gender 41 (54.7%) 15(41.7%) 0.2 12 (48%) 0.7 0.8 
Family history 36 (48%) 15(41.7%) 0.5 11 (44%) 0.8 1 
Hypertension 51 (68%) 27 (75%) 0.5 11 (44%) 0.05 0.01 
Smoking 38 (50.7%) 14(38.9%) 0.31 11 (44%) 0.65 0.8 
Cholesterol 
mmol/l 
6.24±1.25 6.21±1.41 0.92 5.41±0.79 0.002 0.01 
Tryglycerides 
mmol/l 
1.94±1.06 1.82±1.21 0.62 1.27±0.42 0.003 0.03 
BMI>25 43 (57.3%) 26(72.2%) 0.15 12 (48%) 0.49 0.06 
Preivious MI 19 (25.3%) 4 (11.1%) 0.13 0 (0%) 0.003 0.14 
sVCAM-1 
ng/ml 
1447.3±52.9 1362.4±114.9 0.05 1318.6±78.4 0.05 0.419 
sICAM-1 
ng/ml 
465.5±15.9 387.2 ±29.2 0.014 108.6 ±14.7 <0.001 <0.001 
hsCRP mg/l 15.5 ±3.95 2.33 ±0.39 0.025 1.45±0.24 0.048 0.05 
VLF ms 101.4±9.3 195.2±45.3 0.003 213.9±45.1 <0.001 0,78 
LF ms 71.1±8.05 187.6±46.7 <0.001 199.7±43.5 <0.001 0.85 
HF ms 42.1±8.6 87±27.6 0.04 128.4±37.1 0.001 0.37 
LF/HF ms 2.67±0.3 4.09±0.7 0.03 2.12±0.39 0.43 0.06 
Ǿ1 group 1 vs group 2 
Ǿ2 group 1 vs group 3 
Ǿ3 group 2 vs group 3 
Table 1. Baseline characteristics of study population 
3.1.2 Baseline characteristics of patients with ACS according to clinical outcome 
During the six month follow-up of the patients with acute coronary syndromes three 
patients (4%) died suddenly, seventeen (22.7%) suffered a non-fatal myocardial infarction 
and eight (10.7%) had recurrent UA, for a major adverse cardiovascular event rate of 37.3%. 
The majority of ischemic events occurred within 30 days of the initial episode of non ST 
elevation acute coronary syndrome – 16 (57.14%). Simultaneously, the risk of development 
of non-fatal AMI and rehospitalization for recurrent UA remained significant even during a 
longer period of observation as 12 (42,8%) of the subsequent complications occurred during 
the period between the 30th day and the 6th month. 
On Table 2 the demographic, clinical and laboratory data of the patients with major 
cardiovascular events were compared with those of the patients with favorable outcome. 
Both groups do not differ concerning the classical risk factors for the development of 
ischemic heart disease such as age, gender, history of arterial hypertension, tobacco 
smoking, obesity, familial history and indices of lipid profile. The patients have received 
identical drug therapy including heparin (97,3%), acetysal (90,7%), β-blocker (73,3%), nitrate 
(100%), ACE-inhibitor (48%) and diuretics (17,3%). The patients with subsequent 
complications presented more often with Killip class over 1 (28,6% versus 8,5%, p=0,047) 
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and with a significantly lower left ventricular ejection fraction on the echocardiographic 
examination performed between day 3 and day 7 of the hospitalization (54,6% versus 60,4%, 
p=0,003). Concentrations of sVCAM-1 (1488,75 ng/ml versus 1071,45 ng/ml, p<0,001),  
sICAM-1 (516,7 vs 433,3 ng/ml, p=0,010), hsCRP (32.6 vs 5.31 mg/l, p=0.001) and cTnT (0,72 
vs 0,115 ng/ml, p<0,001) at presentation were significantly raised in patients who went on 
to have ischemic events during the six months of follow-up. None of the parameters of HRV 
was significantly associated with the occurrence of the composite endpoint. Although the 
prognostic information of frequency domain HRV indices was low, we found out that 2 
variables – reduced LF (27±1.7 vs 65.1±10 ms, p=0.05) and LF/HF ratio (0.5±0.2 vs 2.94±0.4, 
p=0.004) were significantly predictive of death, but no for other endpoints (Fig 1) 
 
 
No event 
n (%) 
Event 
n (%) 
p 
Number 47 28  
Males 26 (55.3) 15 (53.6) 1 
Age, y 57.36 ±8.2 58.6 ±10.1 0.559 
Hypertension 34 (72.3) 17 (60.7) 0.318 
Smoking 23 (48.9) 15 (53.6) 0.812 
Previous MI 12 (25.5) 7 (25) 1 
Family history 20 (42.6) 16 (57.1) 0.242 
BMI>25 25 (53.2) 18 (64.3) 0.470 
Kilip>1 4 (8.5) 8 (28.6) 0.047 
Cholesterol mmol/l 6.30 ±1.22 6.13 ±1.31 0.581 
Triglycerides mmol/l 2.07 ±1.19 1.70 ±0.75 0.145 
Ejection fraction % 60.4 ±7.65 54.6 ±8.45 0.003 
Тroponin Т ng/ml 0.115 ±0.01 0.72 ±0.16 <0.001 
hsCRP mg/l 5.31 ±1.66 32.59 ±9.45 0.001 
sVCAM-1 ng/ml 1071.5 ±54.08 1488.8 ±90.3 <0.001 
sICAM-1 ng/ml 433.3 ±20.01 516.7 ±23.8 0.010 
VLF ms 114.5±13.4 89.2±11.6 0.16 
LF ms 73.7±12.2 65.2±10.1 0.62 
HF ms 56.6±16.4 32.5±6.5 0.143 
LF/HF ms 1.98±0.3 2.98±0.4 0.07 
Table 2. Baseline characteristics of patients with and without cardiovascular events during 
follow-up 
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Fig. 1. LF and LF/HF in patients according to the prognosis during the study period 
Table 3 presents the associations between soluble adhesion molecules, high sensitivity C-
reactive protein and troponin T in patients with ACS. There is a moderately strong positive 
correlation between the levels of sICAM-1 and sVCAM-1 (Spearman's r=0,205, p=0,028). 
Levels of sICAM-1 showed a strong correlation with hsCRP. The correlation between 
sVCAM-1 and hsCRP was r=0.144, p=0.11. In acute coronary syndromes levels of the 
myocardial necrosis marker troponin T correlated highly significant with hsCRP (r=0.451, 
p=0.001), but showed no interdependence with sVCAM-1 (r=0.106, p=0.383) and sICAM-1 
(r=0.129, p=0.286).  
 
  sVCAM-1 sICAM-1 hsCRP 
sVCAM-1 r 1 0,205 0,144 
 p - 0,028 0,11 
sICAM-1 r 0,205 1 0,438 
 p 0,028 - <0,001 
hsCRP r 0,144 0,438 1 
 p 0,11 <0,001 - 
cTnT r 0,106 0,129 0,451 
 p 0,383 0,286 <0,001 
Table 3. Associations between soluble adhesion molecules, high sensitivity C-reactive 
protein and troponin T 
A nonsignificant inverse correlation was found between sVCAM-1 levels and all HRV 
variables studied with the strongest association with low frequency amplitude. The 
correlation coefficients of hsCRP and cTnT with HRV parameters were low and without 
clinical significance. (table 4) 
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  VLF LF HF LF/HF 
hsCRP r 0,128 -0,02 0,16 -0,19 
 p 0,35 0,87 0,24 0,16 
sVCAM-1 r -0,10 -0,24 -0,12 -0,06 
 p 0,46 0,08 0,41 0,67 
sICAM-1 r -0,08 0,014 0,03 0,009 
 p 0,55 0,92 0,82 0,95 
cTnT r 0,125 0,017 0,15 -0,07 
 p 0,36 0,9 0,27 0,57 
Table 4. Associations between HRV and soluble adhesion molecules, high sensitivity C-
reactive protein and troponin T 
3.1.3 Soluble adhesion molecules and cardiovascular events 
The ROC analysis was performed to provide an index for assessment of the accuracy of the 
variable investigated to discriminate between subjects with cardiovascular complications 
and those without it. The data obtained from it demonstrate threshold concentrations of 0,01 
ng/ml for cTnT (area under the curve 0,803, p=0,001), 4 mg/l for hsCRP (AUC 0,859, 
p=0,001),  1153,4 ng/mL for sVCAM-1 (AUC 0,786, p=0,001) and 438 ng/mL for sICAM-1 
(AUC 0,671, p=0,017) Fig 2.  
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Variable AUC SE 95% Confidence Interval 
CRP 0,859 0,045 0,770 0,948 
cTnT 0,803 0,057 0,692 0,914 
VCAM-1 0,786 0,059 0,669 0,902 
ICAM-1 0,671 0,066 0,542 0,800 
AUC – area under the curve, SE – standard error 
Fig. 2. Receiver-operator characteristic curves of the investigated biomarkers as a test for 
predicting major adverse coronary events in patients with acute coronary syndromes 
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A total of 37 patients (49.3%) had a concentration of sVCAM-1>1153.4 ng/ml and the ischemic 
event rate for these patients was 78.6%. The remaining 38 patients had sVCAM-1 
concentrations <1153.4 ng/ml and the ischemic event rate in this group was 21.4% (Pearson 
x2= 15,28, p<0,001). As Figure 3 A shows the difference was mainly driven by an increased 
rate of non-fatal myocardial infarction and rehospitalsation for unstable angina in the group of 
patients with high sVCAM-1 levels. Although the incidence rate of the ischemic complications 
in the patients with sICAM-1>438 ng/ ml was 66,7% while in the patients with subthreshold 
concentration of this parameter it was only 33,3%, a statistically reliable difference was lacking 
(Pearson x2=2,71,p<0,140, Figure 3 B). The sensitivity of a concentration of sVCAM-1>1153.4 
ng/ml for predicting future ischemic events was 79%, with a specificity of 68%. The negative 
predictive value was 84%. The sensitivity of sICAM-1>438 ng/ml for predicting a future 
ischemic events was 66%, with a specificity of 53% and negative predicting value of 72%.  
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Fig. 3. Cardiovascular events in patients according to concentration of sVCAM-1 (A) and 
sICAM-1 (B) 
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3.1.4 Multivariate risk stratification 
In a multivariate analysis that included baseline characteristics and biochemical markers 
(Table 5) sVCAM-1 remained an independent and powerful predictor of increased cardiac 
risk at 6 months follow-up. The odds ratio associated with the highest value of sVCAM-1 
was 4.62 (95% CI 1.8-11.4, p=0.0009) without adjustment and remained significantly elevated 
after adjustment for Killip class and left ventricular ejection fraction in model 2 (RR 4.63, 1.8-
11.7, p=0.0012), troponin T in model 3 (RR 3.93, 1,5-10, p=0.04) and C-reactive protein in 
model 4 (RR 2.22, 0.8-5.7, p=0.05) Figure 4.   
 
 Odds ratio 95% CI Ǿ 
Sex - Males 0.93 0.44 – 1.97 0.86 
Age > 65 y 1.48 0.68 – 3.21 0.31 
Hypertension 1.38 0.64 – 2.96 0.39 
Smoking 1.11 0.52 – 2.34 0.77 
BMI > 25 1.38 0.6 – 2.9 0.41 
Hypercholesterolemia 1.11 0.45 – 2.76 0.80 
Family history 1.58 0.7 – 3.34 0.23 
Previous MI 1.00 0.42 – 2.37 0.98 
ST depression > 0.5 mm 2.11 0.85 – 5.2 0.10 
Killip > 1 2.73 1.19 – 6.22 0.016 
EF < 50% 2.75 1.24 – 6.11 0.0125 
IǿАМ-1 > 438 ng/ml 1.81 1.82 – 4.04 0.15 
VǿАМ-1 > 1153.4 ng/ml 4.62 1.86 – 11.4 0.0009 
hsǿRP > 4 mg/l 9.85 3.39 – 28.5 <0.0001 
cTnТ > 0.01 ng/ml 5.29 2.13 – 13.1 0.0003 
Table 5. Univariate Cox proportional regression analyses 
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Fig. 4. Multivarate Cox regression models on VCAM-1 as predictor of major adverse 
coronary events during 6 month follow-up 
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In order to assess the exact role of the increased soluble adhesion molecules levels we 
analyzed the combined predictive value of these two molecules with that of the already 
established prognostic indicators among ACS patients – troponin T and hs C-reactive 
protein. Division of the patients into 4 groups based on their sCAM and cTnT levels 
revealed that sVCAM-1 is an independent prognostic indicator of major adverse coronary 
events during the six months follow-up. In the patients admitted to the ICU without any 
detectable levels of the marker of cardiomyocyte necrosis (n=39) the incidence rate of the 
ischemic events was 1,3% when combined with low levels of sVCAM-1 and 6,7% when 
combined with sVCAM-1> 1153,4 ng/ml (Pearson χ2=6,03, p<0,024, Figure 5 A). 
Simultaneously, the high sICAM-1 levels do not improve the prognostic value of troponin T 
as there was no statistically significant difference in the incidence rate of the complications 
in the patients with a negative cTnT test in dependence on the low or high sICAM-1 levels 
(the incidence of the complications was 2,9% and 5,7%, respectively) (Figure 5 B). 
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Fig. 5. Incidence of cardiovascular events according to soluble VCAM-1 and cTnT levels (A) 
and soluble ICAM-1 and cTnT levels (B) 
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Furthermore, the predictive value of VCAM-1 was independent of systemic inflammation as 
evidenced by C-reactive protein. High VCAM-1 serum levels indicated increased cardiac 
risk both in patients with high CRP serum levels (25.3%% vs 6.7%, p=0.024) and in those 
with low CRP serum levels (4% vs 1.3%, p=0.05), Figure 6. 
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Fig. 6. Incidence of cardiovascular events according to soluble VCAM-1 and hsCRP levels 
(A) and soluble ICAM-1 and hsCRP levels (B) 
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3.2 Markers of endothelial activation and impaired autonomic function in patients with 
acute coronary syndromes – Potential therapeutic implication 
3.2.1 Characteristics of the study population 
During the second phase of the study 30 patients with ACS were allocated into two groups, 
and received rosuvastatin 10 mg/day (n =16, mean age 57.25±2.2 years) or rosuvastatin 20 
mg/day (n =14, mean age 57.64±3.1 years) for 12 weeks. Baseline characteristics for each 
group are presented in Table 6, showing no significant differences between the two 
treatment groups. Furthermore, no significant differences in lipids, HRV and markers of 
endothelial activation were observed at baseline. 
 
Variable 
Rosuvastatin 
10 mg 
n=16 
Rosuvastatin 
20 mg 
n=14 
p 
Age 57,25±2,22 57,64±3,1 0.34 
Male gender 7 (23%) 9 (30%) 0.22 
Hypertension 9 (30%) 9 (30%) 0.72 
Smoking 7 (23.3%) 6 (20%) 0.62 
Family history 5 (16.7%) 7 (23.3%) 0.46 
cTnT 0,29±0.13 0,46±0,18 0.91 
EF % 58,5±2,1 58,8±2,6 0.46 
BMI 26,8±1 26,9±1 0.34 
Cholesterol mmol/l 5,66±0,28 6,07±0,32 0.4 
Tryglycerides mmol/l 1,76±0,17 1,93±0,25 0.6 
HDL-C mmol/l 0,99±0,03 0,91±0,03 0.14 
LDL-C mmol/l 3,86±0,29 4,27±0,28 0.3 
sVCAM-1 ng/ml 1235(831.3-1476.3) 1327,4(1039.5-1989.7) 0.21 
sICAM-1 ng/ml 476,8(424,3-516,8) 439,4(362,1-607,3) 0.92 
VLF ms 97±18,7 90,7±16,7 0.80 
LF ms 43,3±8,2 44,5±7,1 0.91 
HF ms 19,8±5,8 20,9±6,7 0.89 
LF/HF ms 3,34±0,5 3,58±0,5 0.77 
Table 6. Baseline characteristics 
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3.2.2 Effects of rosuvastatin on lipid profile and markers of endothelial and autonomic 
activation 
The changes in lipid values from baseline to 12 weeks in the two treatment groups are 
shown in Table 7. 
 
 Rosuvastatin 10 mg Rosuvastatin 20 mg 
 Baseline 3 months p Baseline 3 months p 
Cholesterol 
mmol/l 
5,66±0,28 4,49±0,18 <0.001 6,07±0,32 4,24±0,16 <0.001 
Tryglycerides 
mmol/l 
1,76±0,17 1,3±0,13 <0.001 1,93±0,25 1,37±0,18 <0.001 
HDL-C mmol/l 0,99±0,03 1,05±0,04 <0.001 0,91±0,03 1,06±0,03 <0.001 
LDL-C mmol/l 3,86±0,29 2,67±0,2 <0.001 4,27±0,28 2,27±0,11 <0.001 
Table 7. Effects of rosuvastatin on lipid profile 
Serum levels of total cholesterol, triglycerides and LDL-cholesterol in patients decreased after 
3 months of treatment with rosuvastatin. The decrease in total cholesterol and LDL cholesterol 
was significantly larger in the more aggressively treated group (p<0.05 for all comparisons). 
 
 Rosuvastatin 10 mg Rosuvastatin 20 mg 
 Baseline 3 months p Baseline 3 months p 
sVCAM-1 
median ng/ml 
25- and 75-
percentile 
 
1235 
(831.3-
1476.3) 
 
1120,2 
(839,7-
1341,2) 
 
0.43 
 
1327,4 
(1039.5-1989.7)
 
962,4 
(603,4-
1570,3) 
 
0,01 
sICAM-1 
median ng/ml 
25- and 75-
percentile 
 
476,8 
(424,3-516,8)
 
385,5 
(348,5-453,9)
 
0,004 
 
439,4 
(362,1-607,3)
 
324,7 
(188,5-447,5) 
 
0.01 
VLF ms 97±18,7 99,5±16,5 0,8 90,7±16,7 113,3±20,5 0,35 
LF ms 43,3±8,2 63,8±14,9 0,2 44,5±7,1 56,7±13,4 0,23 
HF ms 19,8±5,8 37±11,6 0,23 20,9±6,7 42,2±7,2 0,009 
LF/HF ms 3,34±0,5 2,87±0,5 0,31 3,58±0,5 1,73±0,2 0,003 
Table 8. Effects of Rosuvastatin on Adhesion Molecules and HRV levels 
After 3 months, patients in the 20 mg rosuvastatin group demonstrated a significant 
decrease in serum levels of sICAM-1 and sVCAM-1 (Table 8, Figure 7 and 8). Also in the 10 
mg-rosuvastin group, there was a significant decrease of sICAM-1 (Figure 9). However, no 
changes in sVCAM-1 levels were observed in this group of patients (Table 8, Figure 10). 
There were no significant differences in changes between the two treatment groups for 
either soluble adhesion molecules levels, but for sICAM-1 we found out a trend towards 
lower concentrations in the moderately treated group (p=0.07). 
No correlations were found between changes in LDL-cholesterol over 12 weeks and changes 
in s-ICAM-1 (r=0.198, p=0.29), sVCAM-1 (r=0.193, p=0.31) and HRV during the same period. 
The Spearman’s correlation coefficients between hsCRP and sICAM-1 (r=0.059, p=0,7) and 
sVCAM-1 (r=0.15, p=0,4) are low and not statistically significant. 
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Fig. 7. Intra-individual changes in levels of s-VCAM-1 in patients during the study. 
 
7
4
7
3
7
2
7
1
6
8
6
5
6
3
6
2
5
9
5
8
5
7
5
6
5
5
5
2
4
9
4
1
3
8
3
6
3
1
3
0
2
6
2
2
2
1
2
0
1
7
1
6
1
1
621
Case Number
1200,00
1000,00
800,00
600,00
400,00
200,00
0,00
IC
A
M
 n
g/
m
l
icam_statin
icam_1
 
Fig. 8. Intra-individual changes in levels of s-ICAM-1 in patients during the study. 
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Fig. 9. Mean changes ± 2 SD of sICAM-1 in the two rosuvastatin treated groups 
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Fig. 10. Mean changes ± 2 SD of sVCAM-1 in the two rosuvastatin treated groups 
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In ACS group, a significant inverse correlation was observed between markers of 
endothelial activation and HRV variables, with the strongest association being found for 
sVCAM-1 and HF amplitude (r =−0.506, p= 0.004) and LF amplitude (r=-0,4, p=0.02). In 
addition, sympathovagal balance was shifted to greater vagal predominance with 20 mg 
rosuvastatin (increase of HF and decrease of low frequency/ high frequency ratio) when 
compared to lower dose of 10 mg, p=0.05, Table 9. 
 
   LDL
vcam 
1 
icam 
1 
VLF LF HF LF/HF 
Spearman's 
rho 
LDL 
Correlation 
Coefficient 
1,000 ,193 ,198 ,049 ,029 ,130 -,098 
Sig. (2-tailed) . ,308 ,294 ,804 ,882 ,509 ,620 
vcam 1
Correlation 
Coefficient 
,193 1,000 ,384(*) -,158
-
,423(*)
-,506 ,207 
Sig. (2-tailed) ,308 . ,036 ,405 ,020 ,004 ,273 
icam 1
Correlation 
Coefficient 
,198 ,384(*) 1,000 ,089 -,144 -,234 ,210 
Sig. (2-tailed) ,294 ,036 . ,654 ,465 ,231 ,284 
VLF 
Correlation 
Coefficient 
,049 -,158 ,089 1,000 ,694 ,431(*) ,125 
Sig. (2-tailed) ,804 ,405 ,654 . ,000 ,017 ,511 
LF 
Correlation 
Coefficient 
,029
-
,423(*)
-,144 ,694 1,000 ,656 ,091 
Sig. (2-tailed) ,882 ,020 ,465 ,000 . ,000 ,634 
HF 
Correlation 
Coefficient 
,130 -,506 -,234 ,431(*) ,656 1,000 -,649 
Sig. (2-tailed) ,509 ,004 ,231 ,017 ,000 . ,000 
LF/HF
Correlation 
Coefficient 
-,098 ,207 ,210 ,125 ,091 -,649 1,000 
Sig. (2-tailed) ,620 ,273 ,284 ,511 ,634 ,000 . 
* Correlation is significant at the 0.05 level (2-tailed). 
Table 9. Associations between HRV and soluble adhesion molecules and LDL cholesterol 
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4. Discussion 
The measurement of ICAM-1 and VCAM-1 in prospective studies is based on the presence 
of an inflammatory process in the artery wall which increases the expression of adhesion 
molecules and on the hypothesis that the serum levels of these molecules reflect their 
expression by the endothelial cells. In this study we had measured the two main 
representatives of the immunoglobulin gene superfamily of CAM and found significantly 
higher levels of both sVCAM-1 and sICAM-1 in patients with ACS as compared with those 
with SAP and healthy controls. Our finding that soluble adhesion molecules and especially 
sVCAM-1 are strongly and independently predictive for future CV events in patient with 
ACS extends previous observations describing the predictive value of inflammatory 
markers on future cardiac events. However, whereas the causative role of C-reactive protein 
in promoting the inflammatory component in development of plaque rupture remains 
controversial, our data implicate a direct mediator of an inflammatory vessel wall process. 
Several arguments support the hypothesis that sCAM may be more useful than other 
markers of inflammation in predicting clinical outcome: 
First, all sICAM-1 and sVCAM-1 measured in our study are elevated in patients at risk for 
future cardiovascular events. Second, sCAM levels did not correlate with cTnT, a specific 
marker of cardiomyocyte necrosis and the most established prognostic marker in patients 
with ACS. The risk related to the high sVCAM-1 concentrations is independent of the cTnT 
that is evident from the increasing rate of complications in the groups with negative and 
positive cTnT in dependence on sVCAM-1 levels. These data suggest that VCAM-1 release 
actually precedes myocardial injury and that VCAM-1 elevation identifies patients with 
unstable atherosclerotic plaque formation even before complete microvascular obstruction. 
In contrast, we do not find any relationship between sICAM-1 and the risk of subsequent 
events in the course of the follow-up and we do not read any enhanced incidence rate of 
vascular events in the patients without laboratory evidence of a cardiomyocyte necrosis in 
dependence on the levels of this parameter. Third, sVCAM-1 levels did not correlate with C-
reactive protein, a systemic marker of inflammation. Because hsCRP correlated with cTnT 
levels elevated CRP serum levels most likely reflect both a robust vascular inflammatory 
response and myocardial injury. The measurement of sVCAM-1 added to the predictive 
value of hsCRP in determining the risk of future cardiovascular events. Even patients with 
low hsCRP levels were found to be at significantly higher risk with elevated sVCAM-1 
levels which suggest that endothelial activation and proteolytic cleavage of sCAM is a 
primary event and is followed by release of other systemic mediators and acute phase 
proteins such as C-reactive protein. 
Prospective data of soluble adhesion molecules are sparse. The results of our study 
correspond to the data published in the literature about the relationship between sCAM and 
the risk of cardiovascular events and they find their explanation in some differences 
between the two adhesion molecules studied. In the large prospective trials ARIC and PHS 
of healthy individuals, sICAM-1, but not sVCAM-1 appears consistently related to incident 
CAD [de Lemos et al., 2000; Hwang et al., 1997; Ridker et al., 1998]. ICAM-1 expression is 
not only endothelial and ICAM-1 is constitutively expressed by a variety of cell types 
including cells of the hematopoietic lineage and fibroblasts. sICAM-1 correlates with acute 
phase reactants like CRP and provides similar predictive information to CRP in settings of 
primary prevention [Blankenberg et al., 2003; Mulvihill et al., 2002; Ridker et al., 1998; 2000]. 
sICAM-1 therefore appears as a general marker of a proinflammatory status with little 
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prognostic information in patients with ACS after controlling the data for troponin T and C-
reactive protein (Figure 5 and 6). By contrast, VCAM-1 is not expressed in baseline 
condition, but is rapidly induced by pro-atherosclerotic conditions in animal models and 
humans [Cybulsky&Gimbronejr, 1991; O’Brien et al., 1993]. It seems that sVCAM-1 
represents an appropriate marker of plaque burden or activity of a potential clinical 
importance as a prognostic indicator under the conditions of secondary prevention rather 
than in healthy individuals without endothelial dysfunction [Blankenberg et al., 2003; 
Mulvihill et al., 2002]. A similar hypothesis is supported by the data proving the 
independent predictive value of sVCAM-1 in the patients with angiographically proven 
coronary artery disease [Blankenberg et al., 2001], with diabetes mellitus [Jager et al., 2000] 
and with ACS [Mulvihill et al., 2001, 2002] as well as its absence in healthy individuals [de 
Lemos et al., 2000]. 
The relationship between depressed HRV and mortality is difficult to ascertain as the 
exact physiological mechanisms responsible for the various HRV components are still 
incompletely known [Task Force of the European Society of Cardiology and the North 
American Society of Pacing and Electrophysiology, 1996; Tsuji et al., 1996]. Decreased 
values of HRV variables, including LF, may reflect reduced vagal tone or predominant 
sympathetic influence to the heart. The presence of frequent or complex non-sustained VA 
in the context of sympathovagal imbalance can increase the susceptibility to fatal VA, in 
particular during myocardial ischaemia [Kent et al., 1973; Lanza et al., 1998, 2006; 
Schwartz et al.,1988]. On the other hand, VA and depressed HRV are unlikely to be 
associated with the triggers of acute MI, as they were not predictive of non-fatal MI in 
hospital or at six-month follow up. 
Recent experimental findings have suggested that the nervous autonomic system can 
significantly modulate inflammatory reactions [Wang et al., 2003]. In particular, vagal 
stimulation has been shown to decrease inflammatory reactions in animals by inhibiting 
tissue macrophage activation, an effect mediated by stimulation of the alpha-7 subunit of 
the macrophage nicotine receptor by the vagal neurotransmitter acetylcholine, whereas 
adrenergic activity has been reported to favor sympathectomy and towards inflammatory 
reactions. Conversely, several products of inflammation have been shown to have potential 
influence on nervous autonomic activity by central and/or peripheral mechanisms [Lanza et 
al.,2006; Tracey,2002]. The low and no significant correlations between markers of 
endothelial activation and HRV in the present study emphasize that neural influence 
unlikely explained the observed predictive value of soluble adhesion molecules in patients 
with ACS. 
ACS is a diffuse process involving the entire coronary vasculature [Buffon et al., 2002]. 
Although mechanical revascularization by percutaneous coronary intervention may address 
the culprit lesion, recurrent events may reflect disease progression or instability elsewhere 
in the vascular tree. Stabilization of vulnerable plaques or modulation of the so-called 
vulnerable patient is becoming recognized as an important target for systemic therapy 
[Libby&Aikawa 2003; Naghavi et al., 2003a, 2003b]. The rapid pleiotropic effects of statins 
on inflammation, endothelial function, and coagulation are likely to be particularly 
beneficial in patients with ACS in whom these systems are deranged. 
Inhibition of HMG CoA reductase by statins inhibits cholesterol synthesis and isoprenoid 
production. This results in reduced prenylation of small G-proteins such as Rho and, in turn, 
NF-κB activation. By inhibiting HMG CoA reductase, statins can prevent the biosynthesis of 
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isoprenoids such as farnesyl pyrophosphate and geranylgeranyl pyrophosphate. Inhibition 
of Rho geranylgeranylation by statins can reduce leukocyte adhesion and fibronolytic 
activity [Rasmussen et al., 2003; Yoshida et al.,2001]. A recent report suggests additional 
mechanism which is independent of mevalonate production - statins bind to a novel 
allosteric site within the ß2-integrin leukocyte function–associated antigen–1 (LFA- 1), 
preventing binding to the counterreceptor on the endothelial surface (ICAM-1) [Weitz-
Schmidt et al., 2001]. 
In addition, statins can induce endothelial nitric oxide synthase (eNOS) accumulation in 
endothelial cells, an effect dependent on the inhibition of Rho geranylgeranylation, reduce 
the activation of monocyte/macrophage system, the cytotoxicity of T-lymphocytes and the 
balance between Th-1/Th-2 subclass. Hence, statins modify the immune response in ACS 
via reductions in inflammatory cell number, adhesion, and activation at potentially 
vulnerable sites along the wall [Liao, 2002; Libby&Aikawa 2003]. 
In animal models HMG-CoA reductase inhibitors have been shown to reduce renal 
sympathetic nerve traffic [Pliquett et al., 2003]. To date, the underlying mechanism by which 
statins reduce sympathetic outflow has not been elucidated. An effect on central nitric oxide 
(NO) and reactive oxygen species (ROS) formation, as well as regulation of the AT1-receptor 
expression, have been proposed as possible explanations [Gao et al., 2005; Gomes et al.,  
2010; Hirooka et al., 2010; Patel et al., 2001]. 
Contradictory results have been published about the effect of statins on sICAM-1 and 
sVCAM-1 plasma/serum concentrations in patients with various clinical manifestation of 
ischemic heart disease. In a number of small population studies, different authors have 
noted that treatment with statins diminished sICAM-1 concentrations in subjects with 
hypercholesterolemia or CHD [Ascer et al., 2004; Patti et al., 2006]. However, Wiklund et 
al., 2002 observed a small and inconsistent effect of simvastatin and atorvastatin treatment 
in hypercholesterolemic patients. Furthermore, Jilma et al., 2003, demonstrated that 
atorvastatin, simvastatin, or pravastatin did not modify sICAM-1 concentrations after 3 
months of treatment in subjects with moderate hypercholesterolemia. Blanco-Colio et al. 
2007, investigate the effect of 10-, 20-, 40- and 80 mg Atorvastatin on sICAM-1 and MCP-1 
levels in 2117 patients with CHD in Achieve Cholesterol Targets Fast with Atorvastatin 
Stratified Titration Trial and didn’t found statistically significant differences between the 
various doses used. Although atorvastatin had a weak effect on sICAM-1 concentrations 
in the whole population [-2.2 % change (95% confidence interval -3.8 to -0.6%); P =.006], in 
the highest quartile all doses of atorvastatin diminished sICAM-1 plasma levels by more 
than 10% in subjects at high cardiovascular risk, indicating that atorvastatin has a greater 
effect in subjects with higher systemic inflammation. In the large PROVE-IT TIMI 22 
study Ray et al. 2006 didn’t found significant difference between intensive (80 mg 
Atorvastatin) and standart (40 mg Pravastatin) regiment on sICAM-1 levels at 30 days. 
However, when considered the relation among statin therapy, sICAM-1 levels, and 
clinical outcomes, the authors found that the risk of adverse events for patients with a 
sICAM-1 level >231 ng/ml appeared more marked among those allocated to standard 
dose statin therapy (each odds ratio >2.1). The observed pattern raises the hypothesis that 
the risk associated with sICAM-1 may be attenuated by treatment with intensive statin 
therapy (each odds ratio <1.5). 
In this study we have analyzed the effect of two rosuvastatin regimens on sICAM-1 and 
sVCAM-1 concentration in patients with high risk ACS defined by the levels of soluble 
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adhesion molecules. We observed that the treatment with rosuvastatin diminish both 
markers of endothelial activation during 12 week follow-up. We found out a trend towards 
lower concentrations of sICAM-1 in patients randomized to 20 mg Rosuvastatin, in addition 
to the previously observed significant lowering of low-density lipoprotein and C-reactive 
protein. There was no correlation between sCAMs and low-density lipoprotein and hsCRP 
at month 3 and the effect of rosuvastatin on soluble CAMs did not appear to be explained by 
changes in lipids or inflammatory markers.  
However, standart statin therapy did not significantly alter sVCAM-1 levels at 3 months. 
The present observations with sVCAM-1 are analogous to the observations with aspirin 
and clopidogrel in which each drug decreases the risk of adverse clinical events in 
subjects with high CRP levels but do not decrease CRP significantly [Chew et al., 2001; 
Kennon et al., 2001; Ridker et al., 1997]. A potential mechanistic explanation for our 
clinical observations is, that among subjects with increased endothelial activation, a more 
potent statin regimen could bind to lymphocyte function-associated antigen-1 on 
inflammatory cells to a greater extent, thus interfering with downstream effects of 
increased endothelial activation rather than decreasing endothelial activation itself. This 
hypothesis raises the possibility that novel therapeutic strategies that target inhibition of 
adhesion molecules may be of benefit in ACS, as has been demonstrated in animal 
models and in patients with inflammatory bowel disease [Gill et al., 2005; Van Assche et 
al., 2005]. 
An interesting finding was the observed beneficial effect of more intense statin regiment 
on some parameters of autonomic function. During the study period we found out a 
significant increase of high frequency component with represents the parasympathetic 
contribution to the spectrum, whereas low frequency remained unchanged. As a result, 
the LF/HF ratio, measure of autonomic balance was reduced significantly in patients 
received 20 mg Rosuvastatin. The results of the correlation analysis clearly suggest that 
some of the beneficial effects of more potent statin dose may be driven by the effect on 
endothelial and autonomic function [Lanza et al., 2006; Patti et al., 2006]. Supports for this 
hypothesis are the results of the meta-analysis of Patti et al, who found that high-dose 
statin pretreatment before percutaneous coronary intervention leads to a significant 
reduction in periprocedural myocardial infarction and 30-day adverse events. It is 
noteworthy that the effect is most pronounced, but is not limited in patients with elevated 
markers of inflammatory activity [Patti et al., 2011]. Our findings must be confirmed by 
larger studies. It may contribute to the achievement of specific treatment goals for each 
patient with proper drug selection and dose titration in high risk patients such as those 
with elevated markers of endothelial activation and depressed HRV. 
5. Conclusions 
In patients with ACS, soluble adhesion molecules are independent predictors of subsequent 
MACE and reduced HRV of medium-term mortality, suggesting that markers of endothelial 
activation and impaired autonomic function should be taken into account in the risk 
stratification of these patients. 
Our findings support the hypothesis that statins decrease endothelial injury and activation 
in patients with acute coronary syndromes. In addition we found that more aggressive 
regiment with early initiation of 20 mg Rosuvastatin significantly decreases sICAM-1 levels 
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and better preserve parasympathetically mediated variable of HRV. Future studies are 
required to elucidate the optimal dose of statin treatment in patients with ACS and high 
levels of markers of inflammatory and endothelial activation or impaired autonomic 
function. 
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